Ethos Technologies announced a record third quarter for 2026, with revenue rising 151% year-over-year to $235.2 million. Both direct channel revenue and third-party channel revenue grew significantly by 112% and 209% respectively, reflecting strong business expansion. The company activated over 140,000 new life insurance policies in Q3, demonstrating robust demand. Ethos projects continued growth with Q4 revenue expected between $220 million and $224 million and full-year revenue forecasted at around $840 million, signaling sustained momentum in democratizing life insurance access.
Ethos Technologies reported a 151% year-over-year revenue increase to $235.2 million in Q3 2026. For readers following the Financials sector, here is Pluang's market snapshot as of Nov 03, 2026 04:11 WIB: Among 142 priced US Financials stocks, 83 rose and 59 fell. Notable movers include RKT at USD 13.70 with a 7.03% gain and 92% buy order activity, GEMI at USD 2.87 down 6.82% with 100% sell orders, and WULF at USD 10.96 down 6.56% with 100% buy orders.
Zentalis Pharmaceuticals awarded 136,000 non-qualified stock options to four newly hired employees as an inducement to join the company, under Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $1.85, matching the stock's closing p...
Dianthus Therapeutics, a clinical-stage biotech company, granted stock options to three new non-executive employees as inducements for joining the company. The options cover 26,000 shares at an exercise price of $82.25, vesting over four years. This ...
The Federal Home Loan Bank of Atlanta announced the election of three new member directors and the re-election of one independent director to its board for 2026. Suzanne DeFerie was named Chair and Kathy McKinney Vice Chair for 2027, ensuring experie...
The FDA placed Bright Minds Biosciences' planned Phase 2 epilepsy trial for BMB-101 on partial clinical hold due to toxicity findings in mice and insufficient pharmacokinetic and juvenile-toxicity data. This action caused a sharp decline in the compa...
NEAR governance approved a plan to reduce the maximum annual issuance of the NEAR token from 2.5% to 1.6%. This change aims to slow the rate at which new tokens enter circulation, potentially impacting staking rewards by lowering them. The plan inclu...
